Search research articles
Contact Us
Filters
Showing results (11-20 of 366) with videos related to
Page
of 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2018
The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost
Mark J Ratain
Nature Reviews. Clinical Oncology
|
August 6, 2014
Targeted therapies: redefining the primary objective of phase I oncology trials
Mark J Ratain
Clinical Advances in Hematology & Oncology : H&O
|
July 29, 2025
Reducing drug toxicity and costs through off-label dosing
Mark J Ratain
Clinical Advances in Hematology & Oncology : H&O
|
August 17, 2012
Importance of food effects for oral oncology drugs
Mark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2010
Bar the windows but open the door to randomization
Mark J Ratain
Clinical Pharmacology and Therapeutics
|
July 13, 2019
Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty
Mark J Ratain
Clinical Pharmacology and Therapeutics
|
April 12, 2024
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
Mark J Ratain
Clinical Advances in Hematology & Oncology : H&O
|
November 14, 2007
The investigational drug steering committee
Mark J Ratain
JCO Oncology Practice
|
July 14, 2022
Oncology Drug Prescribing: The Influences of Greed and Fear
Mark J Ratain
Clinical Advances in Hematology & Oncology : H&O
|
April 9, 2016
Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials
Mark J Ratain
Page
of 37
Search research articles
Search
Showing results (11-20 of 366) with videos related to
Sort By:
Page
of 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2018
The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost
Mark J Ratain
Nature Reviews. Clinical Oncology
|
August 6, 2014
Targeted therapies: redefining the primary objective of phase I oncology trials
Mark J Ratain
Clinical Advances in Hematology & Oncology : H&O
|
July 29, 2025
Reducing drug toxicity and costs through off-label dosing
Mark J Ratain
Clinical Advances in Hematology & Oncology : H&O
|
August 17, 2012
Importance of food effects for oral oncology drugs
Mark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2010
Bar the windows but open the door to randomization
Mark J Ratain
Clinical Pharmacology and Therapeutics
|
July 13, 2019
Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty
Mark J Ratain
Clinical Pharmacology and Therapeutics
|
April 12, 2024
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
Mark J Ratain
Clinical Advances in Hematology & Oncology : H&O
|
November 14, 2007
The investigational drug steering committee
Mark J Ratain
JCO Oncology Practice
|
July 14, 2022
Oncology Drug Prescribing: The Influences of Greed and Fear
Mark J Ratain
Clinical Advances in Hematology & Oncology : H&O
|
April 9, 2016
Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials
Mark J Ratain
Page
of 37